FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380447981> ?p ?o ?g. }

• W4380447981 abstract "Abstract Background and Aims IgA nephropathy (IgAN) is the leading cause of primary glomerulonephritis. Approximately 30-45% of IgAN patients progress to ESKD over a period of 20-25 years and proteinuria is the strongest predictor of disease progression. Endothelin A (ETA) receptor activation drives proteinuria, kidney inflammation and fibrosis. Atrasentan, a potent and selective ETA antagonist, has potential to reduce proteinuria and preserve kidney function in IgAN. Interim results of a phase 2, open-label study in patients with IgAN (AFFINITY, NCT04573920) demonstrated that atrasentan was well tolerated and resulted in clinically meaningful and sustained proteinuria reductions in patients receiving a maximally tolerated and optimized dose of a RAS inhibitor (RASi; Kim et al. 2022, ASN Kidney Week FC052). Sodium glucose cotransporter-2 inhibitors (SGLT2is) are approved for use in adults with CKD at risk of kidney disease progression. In a post-hoc analysis of a global phase 3 study in patients with type 2 diabetes and CKD (SONAR), 6 week treatment with SGLT2i and atrasentan (n = 14) resulted in greater reductions in albuminuria (change in UACR from baseline −54.7%, 95%CI −64.6 to −42.0) compared to atrasentan alone (change in UACR from baseline −37.6%, 95%CI −45.9 to −28.0), suggesting independent and additive effects of both drug classes (Heerspink et al. 2021, Kidney Intl). The ASSIST study will evaluate the safety and efficacy of atrasentan vs. placebo in adults with IgAN and persistent proteinuria while on stable background SGLT2i and RASi therapy. Methods The ASSIST trial is a randomized, double-blind, placebo-controlled, crossover clinical trial. Approximately 52 patients with biopsy-proven IgAN and eGFR ≥ 30 mL/min/1.73 m2 (CKD-epi) who are receiving maximally tolerated RASi for at least 12 weeks prior to screening will be enrolled. Patients on a stable dose of SGLT2i prior to screening (SGLT2i stable) must have total urine protein of &gt;0.5 grams/day at screening. Patients who are not currently on SGLT2i or are not on a stable dose of SGLT2i must have a total urine protein of &gt;0.85 grams/day at screening and enter a run-in period during which they receive SGLT2i for 8 weeks (SGLT2i run-in), after which they must have a total urine protein of &gt;0.5 grams/day confirmed at the Week-1 visit (Figure). Choice of SGLT2i will be at the discretion of the principal investigator and per local treatment standards. Thereafter, all eligible patients will be randomized 1:1 to sequence AB or sequence BA in which they will receive 0.75 mg atrasentan once daily (QD) during one period and placebo during the other period. Randomization will be stratified by SGLT2i status (stable vs run-in). All subjects will enter Treatment Period 1 for 12 weeks, followed by a 12-week washout period, and then Treatment Period 2 for 24 weeks. Following the end of treatment, patients will have follow-up evaluations for safety approximately 4 weeks after the end of treatment. Fifty-two subjects will provide approximately 83% power using a two-sided pairwise test (α 0.05) to detect a treatment effect of at least 0.288 in natural log transformed UPCR (25% reduction) between atrasentan and placebo. Results Primary and secondary endpoints are change in proteinuria (UPCR from 24-hr collection) from baseline to week 12 and week 24, respectively. Type, incidence, severity, seriousness, and relatedness of adverse events will be evaluated. Change in eGFR from baseline to week 24 in Treatment Period 2 will be evaluated as an exploratory endpoint. Conclusion Atrasentan is a potent and selective ETA antagonist. Interim results from the AFFINITY Phase 2 open-label study demonstrated that atrasentan resulted in sustained, clinically meaningful reductions in proteinuria in patients with IgAN. The phase 2 ASSIST study will examine the effects of atrasentan in combination with SGLT2i in patients with IgAN who are also receiving maximally tolerated RASi." @default.
• W4380447981 created "2023-06-14" @default.
• W4380447981 creator A5009128263 @default.
• W4380447981 creator A5017435524 @default.
• W4380447981 creator A5028635098 @default.
• W4380447981 creator A5031510699 @default.
• W4380447981 creator A5037021026 @default.
• W4380447981 creator A5046692355 @default.
• W4380447981 creator A5055078486 @default.
• W4380447981 creator A5060865001 @default.
• W4380447981 creator A5065080507 @default.
• W4380447981 creator A5077188003 @default.
• W4380447981 creator A5085805044 @default.
• W4380447981 date "2023-06-01" @default.
• W4380447981 modified "2023-09-24" @default.
• W4380447981 title "#4341 ASSIST STUDY DESIGN: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN) ON SGLT2I" @default.
• W4380447981 doi "https://doi.org/10.1093/ndt/gfad063c_4341" @default.
• W4380447981 hasPublicationYear "2023" @default.
• W4380447981 type Work @default.
• W4380447981 citedByCount "0" @default.
• W4380447981 crossrefType "journal-article" @default.
• W4380447981 hasAuthorship W4380447981A5009128263 @default.
• W4380447981 hasAuthorship W4380447981A5017435524 @default.
• W4380447981 hasAuthorship W4380447981A5028635098 @default.
• W4380447981 hasAuthorship W4380447981A5031510699 @default.
• W4380447981 hasAuthorship W4380447981A5037021026 @default.
• W4380447981 hasAuthorship W4380447981A5046692355 @default.
• W4380447981 hasAuthorship W4380447981A5055078486 @default.
• W4380447981 hasAuthorship W4380447981A5060865001 @default.
• W4380447981 hasAuthorship W4380447981A5065080507 @default.
• W4380447981 hasAuthorship W4380447981A5077188003 @default.
• W4380447981 hasAuthorship W4380447981A5085805044 @default.
• W4380447981 hasBestOaLocation W43804479811 @default.
• W4380447981 hasConcept C126322002 @default.
• W4380447981 hasConcept C126894567 @default.
• W4380447981 hasConcept C134018914 @default.
• W4380447981 hasConcept C142724271 @default.
• W4380447981 hasConcept C159641895 @default.
• W4380447981 hasConcept C204787440 @default.
• W4380447981 hasConcept C27081682 @default.
• W4380447981 hasConcept C2776174234 @default.
• W4380447981 hasConcept C2778653478 @default.
• W4380447981 hasConcept C2779561371 @default.
• W4380447981 hasConcept C2779922275 @default.
• W4380447981 hasConcept C2780091579 @default.
• W4380447981 hasConcept C2781184683 @default.
• W4380447981 hasConcept C555293320 @default.
• W4380447981 hasConcept C71924100 @default.
• W4380447981 hasConcept C90924648 @default.
• W4380447981 hasConceptScore W4380447981C126322002 @default.
• W4380447981 hasConceptScore W4380447981C126894567 @default.
• W4380447981 hasConceptScore W4380447981C134018914 @default.
• W4380447981 hasConceptScore W4380447981C142724271 @default.
• W4380447981 hasConceptScore W4380447981C159641895 @default.
• W4380447981 hasConceptScore W4380447981C204787440 @default.
• W4380447981 hasConceptScore W4380447981C27081682 @default.
• W4380447981 hasConceptScore W4380447981C2776174234 @default.
• W4380447981 hasConceptScore W4380447981C2778653478 @default.
• W4380447981 hasConceptScore W4380447981C2779561371 @default.
• W4380447981 hasConceptScore W4380447981C2779922275 @default.
• W4380447981 hasConceptScore W4380447981C2780091579 @default.
• W4380447981 hasConceptScore W4380447981C2781184683 @default.
• W4380447981 hasConceptScore W4380447981C555293320 @default.
• W4380447981 hasConceptScore W4380447981C71924100 @default.
• W4380447981 hasConceptScore W4380447981C90924648 @default.
• W4380447981 hasIssue "Supplement_1" @default.
• W4380447981 hasLocation W43804479811 @default.
• W4380447981 hasOpenAccess W4380447981 @default.
• W4380447981 hasPrimaryLocation W43804479811 @default.
• W4380447981 hasRelatedWork W1533697273 @default.
• W4380447981 hasRelatedWork W1569125154 @default.
• W4380447981 hasRelatedWork W2009602329 @default.
• W4380447981 hasRelatedWork W2033456799 @default.
• W4380447981 hasRelatedWork W2376102491 @default.
• W4380447981 hasRelatedWork W2387551403 @default.
• W4380447981 hasRelatedWork W248164375 @default.
• W4380447981 hasRelatedWork W3120820956 @default.
• W4380447981 hasRelatedWork W3148712325 @default.
• W4380447981 hasRelatedWork W4382010788 @default.
• W4380447981 hasVolume "38" @default.
• W4380447981 isParatext "false" @default.
• W4380447981 isRetracted "false" @default.
• W4380447981 workType "article" @default.